Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CLARITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CLARITIN.
BROMPHENIRAMINE MALEATE vs CLARITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity. It inhibits histamine release from mast cells and reduces allergic responses.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
10 mg orally once daily for adults and children ≥6 years.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life 27 hours (range 22-30 hours); clinical context: allows once-daily dosing, steady state reached in 5-7 days
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Renal 40% as metabolites, fecal 40% as metabolites, biliary <5% as unchanged drug
Category C
Category C
Antihistamine
Antihistamine